Ann: AGM Presentation, page-52

Yep - you are totally correct re the standard deviations and probability. But of course, there is just as much chance that the REAL outcome (ie in a statistically robust population) would be minus 43% (which would put a mighty rocket under the share price) as to be plus 20%.

Probability theory suggests it will be somewhere in between. And, of course, that is the purpose of Phase 3 - to identify just how much more or how much less than 17% is the added benefit of DXB-200.

Statistically, at the 95% confidence level, 55% of the potential outcomes (ie those between minus 43% and minus 10%) will fall within the required efficacy range.

But, of course, statistics do not tell the whole story. Clinical specialists, with a lifetime of experience with drug trials have seen enough encouragement in the Phase 2 (albeit with a small sample) to strongly recommend the Phase 3.